Prospects for developing dietary supplements with taxifolin and andrographolide

Introduction. Psoriasis is a chronic immunoinflammatory skin disease with a prevalence of about 2% among the population, characterized by immune system imbalance and excessive production of proinflammatory cytokines. Standard therapy is effective but limited by side effects, creating a need for new safe approaches. Objective: theoretical substantiation of the prospects of combining taxifolin and andrographolide in a gel formulation for adjunctive psoriasis therapy based on analysis of current data on molecular targets of each component. Material and methods. Analysis of current publications in PubMed, Scopus, eLibrary databases using keywords: taxifolin, andrographolide, psoriasis, inflammation, NF-κB, IL-17. Mechanisms of action at cellular and molecular levels, in vitro and in vivo study data were reviewed. Results. Taxifolin primarily modulates inflammatory cascades in keratinocytes through NF-κB/STAT3 blockade, reducing IL-6, IL-8, CCL20 production. Andrographolide affects dendritic cells, reducing IL-6, IL-1β, IL-23 production through autophagic degradation of MyD88. The combined approach covers several key pathogenic mechanisms of psoriasis. Conclusion. The combination of taxifolin and andrographolide has high theoretical substantiation for psoriasis therapy due to complementary mechanisms of action on different parts of the inflammatory cascade and potential synergistic effect.